We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.53%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.06B
AUM Growth
+$54.1M
Cap. Flow
-$57.6M
Cap. Flow %
-5.46%
Top 10 Hldgs %
34.88%
Holding
95
New
10
Increased
31
Reduced
41
Closed
11

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$29.7M
2
ELV icon
Elevance Health
ELV
+$28.1M
3
BDX icon
Becton Dickinson
BDX
+$27.8M
4
PEN icon
Penumbra
PEN
+$10.8M
5
MRK icon
Merck
MRK
+$8.75M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$22.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$18.7M
3
HUM icon
Humana
HUM
+$17.9M
4
LLY icon
Eli Lilly
LLY
+$17M
5
PFE icon
Pfizer
PFE
+$16.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Industrials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$29.8B
$6.32M 0.6%
42,300
+4,800
+13% +$801K
PODD icon
52
Insulet
PODD
$9.9B
$5.96M 0.56%
34,750
+15,750
+83% +$2.94M
IMCR icon
53
Immunocore
IMCR
$1.74B
$5.19M 0.49%
79,778
-4,500
-5% -$309K
XNCR icon
54
Xencor
XNCR
$1.61B
$4.84M 0.46%
218,750
-6,250
-3% -$135K
AVTR icon
55
Avantor
AVTR
$9.23B
$4.37M 0.41%
171,000
-121,000
-41% -$2.88M
SNDX icon
56
Syndax Pharmaceuticals
SNDX
$1.82B
$4.25M 0.4%
+178,500
New +$3.98M
IMVT icon
57
Immunovant
IMVT
$8.18B
$4.05M 0.38%
125,500
-20,561
-14% -$750K
JANX icon
58
Janux Therapeutics
JANX
$1B
$3.93M 0.37%
+104,500
New +$2.28M
KURA icon
59
Kura Oncology
KURA
$875M
$3.55M 0.34%
+166,526
New +$3.24M
RVNC
60
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.45M 0.33%
701,707
+225,835
+47% +$1.34M
CRL icon
61
Charles River Laboratories
CRL
$13.1B
$3.44M 0.33%
12,700
-25,300
-67% -$6.04M
ALPN
62
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.39M 0.32%
+85,500
New +$2.52M
KRYS icon
63
Krystal Biotech
KRYS
$9.84B
$3.38M 0.32%
+19,000
New +$2.64M
AUGX
64
DELISTED
Augmedix, Inc. Common Stock
AUGX
$3.27M 0.31%
+800,000
New +$3.58M
BBIO icon
65
BridgeBio Pharma
BBIO
$16.7B
$3.23M 0.31%
104,500
-30,500
-23% -$1.04M
ALKS icon
66
Alkermes
ALKS
$8.37B
$2.98M 0.28%
110,000
-230,000
-68% -$6.53M
SYK icon
67
Stryker
SYK
$134B
$2.86M 0.27%
8,000
+3,000
+60% +$1.01M
DHR icon
68
Danaher
DHR
$146B
$2.75M 0.26%
11,000
-67,000
-86% -$16.3M
NARI
69
DELISTED
Inari Medical, Inc. Common Stock
NARI
$2.71M 0.26%
+56,420
New +$3.01M
GKOS icon
70
Glaukos
GKOS
$10.6B
$2.55M 0.24%
27,000
-93,000
-78% -$8.31M
EHC icon
71
Encompass Health
EHC
$12.5B
$2.39M 0.23%
+29,000
New +$2.12M
MIRM icon
72
Mirum Pharmaceuticals
MIRM
$6.02B
$2.32M 0.22%
+92,250
New +$2.54M
PRVA icon
73
Privia Health
PRVA
$2.87B
$2.23M 0.21%
114,000
-346,000
-75% -$7.31M
PLRX icon
74
Pliant Therapeutics
PLRX
$65M
$2.16M 0.21%
145,250
+32,509
+29% +$536K
INMB icon
75
INmune Bio
INMB
$56.6M
$2.09M 0.2%
178,284
– –
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rhenman & Partners Asset Management held 95 positions worth $1.06B, up 5.4% from $1B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $57.6M in Q1 2024, closing 11 positions and reducing 41 holdings. Its most notable exit was Humana, an estimated $17.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Becton Dickinson worth $28.7M.

  • Rhenman & Partners Asset Management's largest Q1 2024 buy was Becton Dickinson: 116,000 shares worth $28.7M.
  • Rhenman & Partners Asset Management added most to Cigna in Q1 2024, an estimated $29.7M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2024 reduction was Medtronic, cutting an estimated $22.7M.
  • Rhenman & Partners Asset Management fully exited Humana in Q1 2024, selling an estimated $17.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.06B portfolio in Q1 2024.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 11 in Q1 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2024, filed 14 May 2024.